Boston Scientific Corporation $BSX Shares Acquired by Bank of New Hampshire

Bank of New Hampshire increased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 552.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,724 shares of the medical equipment provider’s stock after acquiring an additional 16,699 shares during the period. Bank of New Hampshire’s holdings in Boston Scientific were worth $2,119,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of BSX. HM Payson & Co. lifted its holdings in Boston Scientific by 1.4% during the 1st quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider’s stock valued at $694,000 after purchasing an additional 98 shares during the last quarter. Park Square Financial Group LLC grew its stake in Boston Scientific by 5.2% during the first quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider’s stock worth $208,000 after buying an additional 103 shares during the last quarter. HHM Wealth Advisors LLC increased its holdings in shares of Boston Scientific by 13.2% during the first quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider’s stock worth $89,000 after buying an additional 103 shares in the last quarter. Rise Advisors LLC increased its holdings in Boston Scientific by 13.9% during the 1st quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider’s stock valued at $85,000 after purchasing an additional 103 shares in the last quarter. Finally, Forum Financial Management LP increased its holdings in Boston Scientific by 0.8% during the 1st quarter. Forum Financial Management LP now owns 13,448 shares of the medical equipment provider’s stock valued at $1,357,000 after purchasing an additional 112 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently commented on BSX shares. Needham & Company LLC restated a “buy” rating and set a $121.00 target price on shares of Boston Scientific in a report on Thursday, September 11th. Raymond James Financial upped their price target on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 24th. Leerink Partnrs raised shares of Boston Scientific to a “strong-buy” rating in a report on Monday, June 16th. Leerink Partners initiated coverage on shares of Boston Scientific in a research note on Monday, June 16th. They issued an “outperform” rating and a $118.00 target price for the company. Finally, Barclays upped their target price on shares of Boston Scientific from $125.00 to $133.00 and gave the stock an “overweight” rating in a research report on Thursday, July 24th. Three analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $118.04.

Boston Scientific Stock Down 2.9%

NYSE:BSX opened at $99.75 on Tuesday. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $109.50. The stock has a 50-day moving average price of $104.78 and a two-hundred day moving average price of $102.24. The stock has a market cap of $147.80 billion, a price-to-earnings ratio of 59.38, a PEG ratio of 2.47 and a beta of 0.65. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to analysts’ expectations of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.Boston Scientific’s revenue for the quarter was up 22.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Edward J. Ludwig sold 4,000 shares of the company’s stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the sale, the director owned 18,479 shares in the company, valued at $1,959,328.37. This represents a 17.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 174,214 shares of company stock worth $18,397,457 over the last 90 days. 0.50% of the stock is currently owned by insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.